Stockscreener 앱 받기
63.84
3.64%
-2.41
시간 외 거래:
63.90
0.06
+0.09%
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Published on: 2026-01-18 16:18:12 - baoquankhu1.vn
Market Catalysts: How cyclical is Arrowhead Pharmaceuticals Incs revenue streamJuly 2025 Chart Watch & Daily Entry Point Alerts - baoquankhu1.vn
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Arrowhead Pharma stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Acquired by Nordea Investment Management AB - MarketBeat
SG Americas Securities LLC Boosts Stake in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Piper Sandler maintains an overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR) - MSN
Arrowhead Pharmaceuticals (ARWR) Stock Analysis: A Biotech Gem with 17% Upside Potential - DirectorsTalk Interviews
Arrowhead Pharma (ARWR) Price Target Raised by Piper Sandler | A - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given "Overweight" Rating at Piper Sandler - MarketBeat
Latham Advises on Arrowhead Pharmaceuticals Upsized Offerings of US$625 Million Convertible Senior Notes, and US$200 Million Common Stock and Pre-Funded Warrants - Legal Desire Media and Insights
Arrowhead Pharmaceuticals at Risk: Potential Generic Competition Threatens REDEMPLO’s Market Exclusivity - MSN
Arrowhead Pharmaceuticals Touts Rudemplo Launch, Obesity RNAi Data and $920M Cash at JPM Conference - MarketBeat
Arrowhead Pharmaceuticals Issues Zero-Coupon 2032 Convertible Notes - TipRanks
Arrowhead Pharmaceuticals Signs Multiple Material Agreements - TradingView — Track All Markets
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events - FinancialContent
Fund Flows: Is Arrowhead Pharmaceuticals Inc gaining market shareWeekly Profit Recap & Capital Efficient Trading Techniques - baoquankhu1.vn
Arrowhead Pharmaceuticals prices upsize convertible notes offering to $625M and stock offering at $64.50 - MSN
A shot in the arm for the innovative drug sector! Piper Sandler bets on Arrowhead, the leader in 'gene silencing', predicting a 55% surge in its stock price. - 富途牛牛
Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR) - Finviz
Arrowhead Pharmaceuticals Reports Transformative Year-End Results - MSN
Will Arrowhead Pharmaceuticals Inc. stock recover faster than peers2025 Analyst Calls & Weekly Setup with High ROI Potential - ulpravda.ru
Technical Reactions to ARWR Trends in Macro Strategies - Stock Traders Daily
Oklahoma City NewsThe Oklahoman - FinancialContent
Finance Watch: Aktis Tests 2026 IPO Waters With Year’s First Offering, Raising $318m - Citeline News & Insights
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approvals And New Obesity Trial Data - Yahoo Finance
Arrowhead’s ARO-DIMERPA Trial Advances in Mixed Hyperlipidemia: What Investors Should Watch - TipRanks
Arrowhead Pharmaceuticals Launches Major Equity and Notes Offerings - TipRanks
Arrowhead Pharmaceuticals (NASDAQ: ARWR) prices equity and 0% 2032 convertible notes offerings - Stock Titan
Will Arrowhead Pharmaceuticals Inc. (HDP1) stock outperform benchmarksChart Signals & Advanced Technical Analysis Signals - ulpravda.ru
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Obesity Trial Progress And New REDEMPLO Approvals - Sahm
Will Arrowhead Pharmaceuticals Inc. stock remain a Wall Street favoriteWeekly Earnings Recap & Weekly Market Pulse Updates - ulpravda.ru
How Arrowhead Pharmaceuticals Inc. (HDP1) stock moves in volatile trading sessions2025 Trading Volume Trends & Technical Pattern Based Signals - ulpravda.ru
Can Arrowhead Pharmaceuticals Inc. stock surprise with earnings upsidePortfolio Gains Summary & Daily Stock Trend Watchlist - ulpravda.ru
Will Arrowhead Pharmaceuticals Inc. (HDP1) stock hit Wall Street targets2025 Price Momentum & Weekly High Momentum Picks - ulpravda.ru
Portfolio Shifts: Can Arrowhead Pharmaceuticals Inc. stock surprise with earnings upsideShare Buyback & Risk Managed Investment Signals - ulpravda.ru
ARWR: Joint Management by Jefferies and JPMorgan in Recent Offering - GuruFocus
Arrowhead Pharmaceuticals prices $625 million convertible notes offering By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants - BioSpace
Arrowhead Pharmaceuticals (ARWR) Unveils $625M Convertible Notes Offering - GuruFocus
Arrowhead Pharmaceuticals Shares Early RNAi Obesity Data, Highlights Visceral Fat Drops and Combo Potential - MarketBeat
Arrowhead Pharmaceuticals prices $625 million convertible notes offering - Investing.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment ApproachesSlideshow (NASDAQ:ARWR) 2026-01-07 - Seeking Alpha
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Raised to $85.00 - MarketBeat
ARWR: Goldman Sachs Raises Arrowhead Pharma's Price Target to $8 - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap DownHere's What Happened - MarketBeat
Arrowhead Pharmaceuticals (ARWR) details $200M stock offering and $500M 2032 convertible notes - Stock Titan
Arrowhead Pharma (ARWR) Sees Target Price Boost by Morgan Stanley | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals shares down 7.8% after co announces stock sale, convertible bond offering - marketscreener.com
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China - BioSpace
Bernstein reiterates Market Perform rating on Arrowhead Pharma stock By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals (ARWR) Gains Approval in China for Red - GuruFocus
Arrowhead Pharma stock rating reiterated by Cantor Fitzgerald on obesity data - Investing.com Canada
Chardan Capital Raises Price Target for Arrowhead Pharma (ARWR) to $80.00 | ARWR Stock News - GuruFocus
Chardan Capital Raises Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $80.00 - MarketBeat
4.73%
0.92%
자본화:
|
볼륨(24시간):